The chief executive of pharmaceuticals giant AstraZeneca has written to staff to stifle rumours he is planning to leave the company to move to an Israeli rival.
Pascal Soriot told staff in a memo earlier this week that he expects to work with employees to see the company succeed, according to Reuters.
Together, we are poised to achieve something remarkable and that few thought possible.
Nothing can break the momentum you have established, and certainly not rumours.
Astra's shares jumped in May this year after it announced a successful trial of a late-stage lung cancer drug trial commonly known as Mystic. The company is now awaiting critical data on the drug.
The findings of that trial may be announced at the European Society for Medical Oncology annual meeting in September, which an Astra spokesperson has confirmed Soriot will attend.
Shares in FTSE 100-listed AstraZeneca were up 0.64 per cent at 5,147p at the time of publishing.